Literature DB >> 3484382

Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes.

A Rahman, A Ganjei, J R Neefe.   

Abstract

The immunologic and pharmacologic effects of free doxorubicin and of doxorubicin entrapped in liposomes were compared in mice at a dose of 20 mg/kg. Liposomes for encapsulation of doxorubicin were prepared by using 39.35 mumol drug, 19.65 mumol cardiolipin, 100 mumol phosphatidylcholine, 68.4 mumol cholesterol, and 38.9 mumol stearylamine. Pharmacologic disposition studies after a dose of 20 mg/kg demonstrated 7- to 10-fold higher drug concentrations in the spleen at all time points following administration of doxorubicin entrapped in cardiolipin liposomes than after the free drug. The levels in liver were 4- to 5-fold higher with liposomal drug, whereas the cardiac uptake with liposomal doxorubicin was significantly lower than with free drug. Mice were sacrificed on days 1, 8, 15, and 22 after drug administration and spleen cells were isolated for studies of sensitization to alloantigens for cell-mediated cytolysis and of proliferation in response to mitogens. Mice treated with free doxorubicin demonstrated a decrease of more than 50 fold (compared with saline control) in allospecific cytotoxic activity on day 15; normal levels were recovered by day 22. The animals treated with doxorubicin encapsulated in liposomes showed a similar but not more pronounced fall to low levels. The total lytic activity per spleen after free drug or drug encapsulated in liposomes was markedly reduced at day 8, but this activity was fully recovered by day 15 in animals receiving liposomal doxorubicin; in those receiving free drug it had not recovered fully even at day 22. The proliferative response to concanavalin A was affected by the two forms of doxorubicin in a pattern very similar to the cytotoxic response. The proliferative response to lipopolysaccharide was markedly depressed by doxorubicin delivered in either form, and the kinetics were not altered by the mode of administration. The concentration of doxorubicin in spleen was markedly increased with liposomal delivery, but did not result in greater toxicity than that of free drug according to the immunologic parameters evaluated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484382     DOI: 10.1007/BF00255282

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  29 in total

1.  Treatment of Ewing's sarcoma with adriamycin (NSC-123127).

Authors:  R K Oldham; T C Pomeroy
Journal:  Cancer Chemother Rep       Date:  1972-10

2.  Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease.

Authors:  J J Wang; E Cortes; L F Sinks; J F Holland
Journal:  Cancer       Date:  1971-10       Impact factor: 6.860

3.  Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods.

Authors:  N R Bachur; A L Moore; J G Bernstein; A Liu
Journal:  Cancer Chemother Rep       Date:  1970-04

4.  Targeting of drugs.

Authors:  G Gregoriadis
Journal:  Nature       Date:  1977-02-03       Impact factor: 49.962

5.  Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice.

Authors:  A Gabizon; A Dagan; D Goren; Y Barenholz; Z Fuks
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

6.  Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes.

Authors:  K Mehta; G Lopez-Berestein; E M Hersh; R L Juliano
Journal:  J Reticuloendothel Soc       Date:  1982-08

7.  Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin.

Authors:  R L Juliano; D Stamp
Journal:  Biochem Pharmacol       Date:  1978-01-01       Impact factor: 5.858

8.  Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration.

Authors:  A Rahman; N More; P S Schein
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

9.  Fluorescence assays and pharmacokinetic studies of 4'-deoxydoxorubicin and doxorubicin in organs of mice bearing solid tumors.

Authors:  F Formelli; C Pollini; A M Casazza; A di Marco; A Mariani
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

10.  Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes.

Authors:  A Rahman; G White; N More; P S Schein
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

View more
  8 in total

1.  Disposition of ultrasound sensitive polymeric drug carrier in a rat hepatocellular carcinoma model.

Authors:  Michael C Cochran; John R Eisenbrey; Michael C Soulen; Susan M Schultz; Richard O Ouma; Sarah B White; Emma E Furth; Margaret A Wheatley
Journal:  Acad Radiol       Date:  2011-11       Impact factor: 3.173

Review 2.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

3.  Incorporation of chlorpromazine into bilayer liposomes for protection against microsomal metabolism and liver absorption.

Authors:  R A Schwendener
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Apr-Jun       Impact factor: 2.441

4.  A phase II trial of doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma.

Authors:  G K Schwartz; E S Casper
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

5.  Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.

Authors:  K M Rentsch; D H Horber; R A Schwendener; H Wunderli-Allenspach; E Hänseler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation.

Authors:  P C Gokhale; B Radhakrishnan; S R Husain; D R Abernethy; R Sacher; A Dritschilo; A Rahman
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

7.  Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.

Authors:  A Rahman; A Joher; J R Neefe
Journal:  Br J Cancer       Date:  1986-09       Impact factor: 7.640

8.  Ehrlich tumor inhibition using doxorubicin containing liposomes.

Authors:  Nihal Saad Elbialy; Mohsen Mahmoud Mady
Journal:  Saudi Pharm J       Date:  2014-07-10       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.